TargetMol台灣代理商卓昇有限公司 交貨迅速 品質有保障 電話: 02-2736 7100
TargetMol Chemicals Inc. 總部位於馬薩諸塞州波士頓，專門提供滿足全球化學和生物科學家研究需求的產品和服務。 TargetMol 在 40 多個國家擁有客戶群，現已發展成為全球最大的化合物庫和小分子化合物研究供應商之一。
TargetMol 努力更新並提供超過 160 種化合物庫和廣泛的高質量研究化學品，包括用於實驗室和科學用途的抑製劑、活化劑、天然產物、肽、抗體和新型生命科學試劑盒。此外，我們的實驗室允許我們進行 CADD（計算機輔助藥物設計）和化學合成，以滿足客戶的定制需求.
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
TargetMol diligently updates and offers over 160 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies, and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
More information visit: https://www.targetmol.com
訂購TargetMol專線請洽: 卓昇有限公司 (02)2736 7100 或 0800 088 700
我要詢價/訂貨
Compound Libraries
- Approved / Repurposing
- Characteristic Bioactive Libraries
- COVID-19 / SARS-CoV-2
- Disease Focused
- Target / Pathway Focused
- Natural Product Libraries
- Characteristic Natural Product Libraries
- Natural Compound Library for HTS
- Natural Product Based LibrarySelectable Natural
- Compound Library
- Fragment LibrariesCustom Compound Library
Apoptosis
Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide.
Endocrinology
Found in most species of the animal kingdom, the endocrine system
Microbiology
Microbiology is the study of microscopic organisms.
Inflammation
/Immunology
The diseases caused by disorders of the immune system fall into two broad
Metabolic Disease
Metabolic diseases is defined by a constellation of interconnected physiological
Neurological Disease
A range of neurological disorders, including epilepsy and dystonia
Inhibitory Antibodies
| Cat No. | product name | ||
|---|---|---|---|
| T9916 | Alirocumab | Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture. | |
| T9920 | Evolocumab | Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9). | |
| T9921 | Infliximab | Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn’s disease and rheumatoid arthritis. | |
| T9919 | Alemtuzumab | Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen found on the surface of normal and malignant lymphocytes. | |
| T9915 | Eculizumab | Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5 | |
| T9926 | Omalizumab | Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) | |
| T9927 | Panitumumab | Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). | |
| T9922 | Matuzumab | Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR, frequently associated with the growth of blood vessels in… | |
| T9928 | Ranibizumab | Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A | |
| T9917 | Denosumab | Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand | |
| T9925 | Ofatumumab | Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation | |
| T9923 | Nimotuzumab | Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). | |
| T9930 | Secukinumab | Secukinumab is a fully humanized, monoclonal anti-IL-17A antibody, and the first in its class to be approved by the US Food and Drug Administration for the treat… | |
| T9918 | Daratumumab | Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. | |
| T9929 | Ramucirumab | Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. | |
| T9924 | Obinutuzumab/afutuzumab | Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma. | |
| T9901 | Adalimumab | Adalimumab (anti-TNF-alpha) is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha. | |
| T9902 | Atezolizumab | Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of… | |
| T9903 | Avelumab | Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. | |
| T9904 | Bevacizumab | Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity. | |
| T9906 | Ipilimumab | Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibit… | |
| T9907 | Nivolumab | Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human ce… | |
| T9908 | Pembrolizumab | Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy. | |
| T9909 | Pertuzumab | Pertuzumab (anti-HER2), a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2… | |
| T9910 | Rituximab | Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM. | |
| T9911 | Tocilizumab | Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor | |
| T9912 | Trastuzumab | Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER… | |
| T9913 | Ustekinumab | Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody. | |
| T9914 | Vedolizumab | Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn’s disease. |
ALK
Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246) is an enzyme that in humans is encoded by the ALK gene.The receptor ALK plays a pivotal role in cellular communication and in the normal development and function of the nervous system.
| Cat No. | product name | |||||||
|---|---|---|---|---|---|---|---|---|
| T1661 | CrizotinibHOT | Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor. |
| |||||
| T1791 | LDK378HOT | Ceritinib (LDK378) is a specific ALK inhibitor (IC50: 0.2 nM). | ||||||
| T1935 | LDN193189HOT | LDN193189 (DM 3189) is a selective BMP signaling inhibitor, inhibiting the transcriptional activity of ALK2 and ALK3 (IC50s: 0.8/0.8/5.3/16.7 nM for ALK1/2/3/6)…. | ||||||
| T1763 | SB525334HOT | SB-525334 is a potent and selective inhibitor of the TGF-β1R and ALK5 (IC50: 14.3 nM). | ||||||
| T1726 | SB 431542HOT | SB-431542 is a potent and selective inhibitor of ALK5 (IC50: 94 nM) and is also an inhibitor of ALK4 (IC50: 140 nM) and ALK7. |
| |||||
| T2655 | CEP37440 | CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK). | ||||||
| T2098 | A77-01 | A 77-01 is a potent inhibitor of TGF-(beta) type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM. | ||||||
| T1800 | GW 788388 | GW788388 is a potent and selective inhibitor of ALK5, also inhibits TGF-(beta) type II receptor and activin type II receptor activities. | ||||||
| T6337 | RepSox | RepSox is a potent and selective of the TGFβR-1/ALK5 inhibitor. | ||||||
| T2449 | D 4476 | D4476 is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay). | ||||||
| T1944 | LDN214117 | LDN-214117 is a potent and selective ALK2 inhibitor. | ||||||
| T2641 | KRCA0008 | KRCA-0008 is an effective and specific ALK/Ack1 inhibitor (IC50: 12/4 nM); displays drug-like properties without hERG liability. | ||||||
| T3061 | Lorlatinib | PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), wit… |
| |||||
| T1900 | LDN212854 | LDN-212854, a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versu… | ||||||
| T1914 | K 02288 | K02288 is a novel small molecule inhibitor of ALK1/2/3/6. | ||||||
| T9224 | CH5424802 analog | CH5424802 analog is a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. | ||||||
| T3550 | Ensartinib | Ensartinib (X-396) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic… | ||||||
| T2462 | SB505124 | SB505124 is a selective inhibitor of TGFβR for ALK4, ALK5. | ||||||
| T6496 | Vactosertib | Vactosertib is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as act… |
| |||||
| T1936 | Alectinib | CH5424802 is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. | ||||||
| T1942 | DMH1 | DMH-1 is a potent and selective BMP inhibitor. |
| |||||
| T3059 | AP26113 | AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. P… | ||||||
| T3621 | Brigatinib | Brigatinib is a highly potent and selective ALK inhibitor. | ||||||
| T3079 | GSK1838705A | GSK1838705A is an effective IGF-1R inhibitor (IC50: 2.0 nM), modestly potent to IR (IC50: 1.6 nM) and ALK (IC50: 0.5 nM), respectively, and little inhibition to … | ||||||
| T3678 | Entrectinib | Entrectinib is an inhibitor of TrkA (IC50: 1.7 nM), TrkB (IC50: 0.1 nM), and TrkC (IC50: 0.1 nM), as well as anaplastic lymphoma kinase (ALK; IC50: 1.6 nM) and C… |
| |||||
| T1962 | ASP 3026 | ASP3026 has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Posit… | ||||||
| T6158 | LDN-193189 HCl | LDN193189 hydrochloride is a selective BMP type I receptor kinases inhibitor. | ||||||
| T1943 | ML347 | ML347(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3. | ||||||
| T1967 | AZD3463 | AZD3463, an orally bioavailable ALK inhibitor (Ki: 0.75 nM), can inhibit IGF1R with equivalent potency. | ||||||
| T2251 | TAE684 | NVP-TAE 684 is a excellently effective and specific ALK inhibitor(IC50=3 nM). | ||||||
| T3041 | ALK inhibitor 2 | ALK inhibitor 2 is a new-type and selective inhibitor for the ALK kinase. | ||||||
| T10283 | ALK-IN-5 | ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK, IC50: 2.9 nM). | ||||||
| T1791L | LDK378 dihydrochloride | Ceritinib dihydrochloride is a selective, orally bioavailable and ATP-competitive inhibitor of ALK tyrosine kinase(IC50 of 200 pM), and also inhibits IGF-1R, Ins… | ||||||
| T13421 | (-)-Cevimeline hydrochloride hemihydrate | (-)-Cevimeline hydrochloride hemihydrate is an agonist of muscarinic receptor. | ||||||
| T13416 | ZX-29 | ZX-29 is a potent and selective inhibitor of ALK(IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively), and also induces … | ||||||
| T13352 | Wy 49051 | Wy 49051 is an orally active antagonist of H1 receptor(IC50 of 44 nM). | ||||||
| T16708 | R-268712 | R-268712 is a specific activin receptor-like kinase 5 (ALK5) inhibitor(IC50 of 2.5 nM). It is also an orally active transforming growth factor-β type I receptor… | ||||||
| T15572 | IN-1130 | IN-1130 is a highly selective inhibitor of transforming growth factor-β type I receptor kinase (ALK5) (IC50: 5.3 nM for ALK5-mediated Smad3 phosphorylation). IN… | ||||||
| T10759 | CEP-28122 mesylate salt (1022958-60-6 free base) | CEP-28122 mesylate salt is a highly selective orally active ALK inhibitor (IC50: 1.9 nM in an enzyme-based TRF assay). | ||||||
| T11254 | F-1 | F-1 is IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. F-1 is a potent ALK and ROS1 dual inhibitor, suppres… | ||||||
| T13138 | TGFBR1-IN-1 | TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM). | ||||||
| T15262 | Vactosertib Hydrochloride | Vactosertib Hydrochloride is an orally active and ATP-competitive ALK5 inhibitor (IC50: 12.9 nM). It has potently antimetastatic activity and anticancer effect. … | ||||||
| T13564 | AZ7550 | AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM). | ||||||
| T10426 | AZ12601011 | AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor (IC50: 18 nM; Kd: 2.9 nM) with inhibitory to mammary tumor growth. AZ12601011 inhibits phosphor… | ||||||
| T10287 | ALK2-IN-2 | ALK2-IN-2 is a potent and selective inhibitor of ALK2 (IC50: 9 nM), and over 700-fold selectivity against ALK3. | ||||||
| T22324 | Ensartinib dihydrochloride | Ensartinib dihydrochloride is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK… | ||||||
| T10442 | A 83-01 sodium salt | A 83-01 sodium salt is a potent inhibitor of ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50s: 12, 45 and 7.5 nM against the… | ||||||
| T13781 | MS4077 | MS4077 is an degrader of anaplastic lymphoma kinase (ALK) PROTAC(Kd of 37 nM for binding affinity to ALK). | ||||||
| T8387 | Alectinib hydrochloride | Alectinib hydrochloride is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM) | ||||||
| T8399 | Crizotinib hydrochloride | Crizotinib hydrochloride is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM) | ||||||
| T8108 | Blu-782 | Blu-782 is a activin receptor-like kinase-2 (ALK2) inhibitor ( IC50 of <10 nM) | ||||||
| T8152 | 6-Demethoxytangeretin | 6-Demethoxytangeretin is a citrus flavonoid isolated from Citrus depressa. | ||||||
| T5197 | BIBF0775 | BIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM). | ||||||
| T4975 | SM 16 | SM 16 is a ALK5/ALK4 kinase inhibitor (Ki: 10/1.5 nM). | ||||||
| T4071 | TPX0005 | TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively. |
| |||||
| T4257 | Belizatinib | Belizatinib is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC. | ||||||
| T4015 | HG-14-10-04 | HG-14-10-04 is a potent and specific ALK inhibitor. | ||||||
| T3031 | ALK5 Inhibitor IV | A 83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 with IC50 values of 12 … | ||||||
| T2612 | CEP28122 | CEP-28122 is a highly potent and selective orally active ALK inhibitor. |